Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-05
2007-06-05
Tate, Christopher R. (Department: 1654)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
Reexamination Certificate
active
09980672
ABSTRACT:
A method of causing cardiomyocyte growth and/or differentiation, the method comprising exposing a cardiomyocyte to neuregulin (NRG) thereby activating the MAP kinase pathway in the cardiomyocyte and causing growth and/or differentiation of the cardiomyocyte. Use of neuregulin, neuregulin polypeptide, neuregulin derivatives, or compounds which mimic the activities of neuregulins in the treatment or management of heart disease and heart failure in a mammal.
REFERENCES:
patent: 3773919 (1973-11-01), Boswell et al.
patent: 4179337 (1979-12-01), Davis et al.
patent: 4301144 (1981-11-01), Iwashita et al.
patent: 4485045 (1984-11-01), Regen
patent: 4496689 (1985-01-01), Mitra
patent: 4544545 (1985-10-01), Ryan et al.
patent: 4640835 (1987-02-01), Shimizu et al.
patent: 4670417 (1987-06-01), Iwasaki et al.
patent: 4791192 (1988-12-01), Nakagawa et al.
patent: 5367060 (1994-11-01), Vandlen et al.
patent: 5530109 (1996-06-01), Goodearl et al.
patent: 5641869 (1997-06-01), Vandlen et al.
patent: 5667780 (1997-09-01), Ho
patent: 5714385 (1998-02-01), Mather et al.
patent: 5716930 (1998-02-01), Goodearl et al.
patent: 5721139 (1998-02-01), Mather et al.
patent: 5834229 (1998-11-01), Vandlen et al.
patent: 5840525 (1998-11-01), Vandlen et al.
patent: 5856110 (1999-01-01), Vandlen et al.
patent: 5859206 (1999-01-01), Vandlen et al.
patent: 5968511 (1999-10-01), Akita et al.
patent: 6033660 (2000-03-01), Mather et al.
patent: 6087323 (2000-07-01), Gwynne et al.
patent: 6096873 (2000-08-01), Schaefer et al.
patent: 6121415 (2000-09-01), Godowski et al.
patent: 6136558 (2000-10-01), Ballinger et al.
patent: 6156728 (2000-12-01), Gao
patent: 6162641 (2000-12-01), Goldman et al.
patent: 6169070 (2001-01-01), Chen et al.
patent: 6252051 (2001-06-01), Godowski et al.
patent: 6387638 (2002-05-01), Ballinger et al.
patent: 6399746 (2002-06-01), Vandlen et al.
patent: 6444642 (2002-09-01), Sklar et al.
patent: 6446242 (2002-09-01), Lien et al.
patent: 6593290 (2003-07-01), Gao
patent: 6635249 (2003-10-01), Marchionni et al.
patent: 6750196 (2004-06-01), Reh et al.
patent: 68278/94 (1994-11-01), None
patent: 3218121 (1982-05-01), None
patent: 102324 (1983-07-01), None
patent: 133988 (1984-08-01), None
patent: 52322 (1985-03-01), None
patent: 58481 (1986-10-01), None
patent: 88046 (1987-12-01), None
patent: 143949 (1988-10-01), None
patent: 36676 (1990-09-01), None
patent: 142641 (1991-01-01), None
patent: 647449 (1994-06-01), None
patent: 83-118008 (1983-06-01), None
patent: WO 89/01489 (1989-02-01), None
patent: WO 92/18627 (1992-10-01), None
patent: WO 94/00140 (1994-01-01), None
patent: 26298 (1994-05-01), None
patent: WO 94/26298 (1994-05-01), None
patent: WO 94/26298 (1994-11-01), None
patent: WO 95/32724 (1995-12-01), None
patent: WO 96/15812 (1996-05-01), None
patent: WO 96/15812 (1996-05-01), None
patent: WO 97/09425 (1997-03-01), None
patent: 18976 (1999-04-01), None
patent: WO 99/18976 (1999-04-01), None
Balligand et al. Cardiac endothelium and tissue growth. Progress in Cardiovascular Diseases (Jan./Feb. 1997),; 3(4):351-360.
Balligand et al.“Cardiac Endothelium and Tissue Growth” Progress in Cardiovascular Diseases (1997) 39(4):351-360.
Chien et al. “Regulation of Cardiac Gene Expression During Myocardial Growth and Hypertrophy: Molecular Studies of an Adaptive Physiologic Response” FASEB Journal (1991) 5:3037-3046.
Colucci et al. “Pathphysiology of Heart Failure” Chapter 13In Heart Disease: A Textbook of Cardiovascular MedicineBraunwald, ed. Saunders, Philadelphia. (1996) 5:394-420.
Dias et al. “The Molecular Basis of Skeletal Muscle Differentiation” Seminars in Diagnostic Pathology (1994) 11(1):3-14.
Epstein et al “Biological Activity of Liposome-Encapsulated Murine Interferon γ is Mediated by a Cell Membrane Receptor” Proc. Natl. Acad. Sci. USA (1985) 82:3688-3692.
Florini-Jr. et al. “Stimulation of Myogenic Differentiation by a Neuregulin, Glial Growth Factor 2” Journal of Biological Chemistry 271(22):12699-12702 (1996).
Hwang et al. “Hepatic Uptake and Degradation of Unilamellar Sphingomyelin/Cholesterol Liposomes: A Kinetic Study” Proc. Natl. Acad. Sci. USA (1980) 77:4030-4034.
Langer et al. “Biocompatibility of Polymeric Delivery Systems for Macromolecules” Journal of Biomedical Materials Research (1981) 15:267-277.
Parker et al. “p53-Independent Expression of p21Cip1in Muscle and Other Terminally Differentiating Cells” Science (1995) 267:1024-1027.
Physicians Desk Reference.(1994) Medical Economics Data Production Co., Montvale, NJ. pp. 2314-2320.
Rumyantsev “Interrelations of the Proliferation and Differentiation Processes During Cardiac Myogenesis and Regeneration” International Review Cytology (1977) 51:187-273.
Sidman et al. “Controlled Release of Macromolecules and Pharmaceuticals from Synthetic Polypeptides Based on Glutamic Acid” Biopolymers (1983) 22:547-556.
Simpson et al. “Myocyte Hypertrophy in Neonatal Rat Heart Cultures and Its Regulation by Serum and by Catecholamines” Circulation Research (1982) 51(6):787-801.
Zhao et al. “Neuregulins Promote Survival and Growth of Cardiac Myocytes” The Journal of Biological Chemistry (1998) 273(17):10261-10269.
Zhao et al. “Selective Disruption of Neuregulin-1 Function in Vertebrate Embryos Using Ribozyme-tRNA Transgenes” Development 125:1899-1907 (1998).
Zhou et al. “Retinoid-Dependent Pathways Suppress Myocardial Cell Hypertrophy” Proc. Natl. Acad. Sci. USA (1995) 92:7391-7395.
Holmes, et al., “Identification of Heregulin, a Specific Activator of p185.sup.erbB2,” Science 256:1205-1210 (1992).
Audet Maury
Jones Day
Tate Christopher R.
Zensun (Shanghai) Science & Technology Limited
LandOfFree
Cardiac muscle function and manipulation does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Cardiac muscle function and manipulation, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Cardiac muscle function and manipulation will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3828371